CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 Cyclerion Therapeutics (NASDAQ: CYCN ) just reported results for the first quarter of 2024. Cyclerion Therapeutics reported earnings per share of -62 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 appeared first on InvestorPlace .
CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 Cyclerion Therapeutics (NASDAQ: CYCN ) just reported results for the fourth quarter of 2023. Cyclerion Therapeutics reported earnings per share of -$1.60. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 appeared first on InvestorPlace .
Cyclerion Therapeutics appoints Graul as President Regina Graul, Ph.D., has been appointed as President of Cyclerion Therapeutics, where she will lead the organization and spearhead strategic initiatives.
Cyclerion Appoints Regina Graul, Ph.D., as President – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy –
Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday''s Mid-Day Session Gainers Harbor Custom Development, Inc. (NASDAQ: HCDI ) rose 74.2% to $1.50 after surging 24% on Thursday. Altimmune, Inc. (NASDAQ: ALT ) shares surged 45.5% to $4.60 after the company reported topline results from MOMENTUM 48-week Phase 2 obesity trial of pemvidutide. ShiftPixy, Inc. (NASDAQ: PIXY ) gained 44.3% to $12.05 after gaining over 43% on Thursday. Elastic N.V. (NASDAQ: ESTC ) gained 30.3% to $104.72 after the company reported better-than-expected second-quarter financial results and issued guidance. UiPath Inc. (NYSE: PATH ) shares climbed 25.2% to $24.74 after the company reported upbeat third-quarter financial results on Thursday. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) rose 22.6% to $2.65. CleanSpark, Inc. (NASDAQ: CLSK ) gained 20.6% to $7.53 following FY23 results. Tenon Medical, Inc. (NASDAQ: TNON ) climbed 20.5% to $2.3490. Limoneira Company (NASDAQ: LMNR ) gained 16.5% to $17.70 as the company announced process to explore strategic alternatives to maximize value.
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment –
Cyclerion Therapeutics in compliance with Nasdaq minimum bid price rule Cyclerion Therapeutics (CYCN) has received a formal notice from The Nasdaq stating that it has regained compliance with the $1/share minimum bid price requirement pursuant to…
Cyclerion announces 1 for 20 reverse stock split Cyclerion Therapeutics (CYCN) announced a reverse stock split of its outstanding common shares at a ratio of 1-for-20, effective as of 5:00 p.m
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors Cyclerion Therapeutics Inc (NASDAQ: CYCN ) has agreed to sell two of its assets - zagociguat (formerly CY6463) and CY3018, to a new private company ("NewCo") formed by certain current Cyclerion shareholders and new investors who have agreed to invest $81 million . Cyclerion will receive $8 million as reimbursement for all expenses related to zagociguat and CY3018 between the signing and closing of the transaction and 10% equity ownership in NewCo. Cyclerion will also have additional future … Full story available on Benzinga.com